Skip to main content
Clinical Trials/NCT06296186
NCT06296186
Recruiting
Not Applicable

Clinical Effectiveness and Implementation of Massed Prolonged Exposure for PTSD Among Veterans in Intensive Outpatient Substance Use Treatment (MPE)

Veterans Medical Research Foundation4 sites in 1 country200 target enrollmentSeptember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stress Disorders, Post-Traumatic
Sponsor
Veterans Medical Research Foundation
Enrollment
200
Locations
4
Primary Endpoint
Time Line Follow back (TLFB)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to learn if receiving Prolonged Exposure Therapy for PTSD in massed format (multiple sessions weekly) is as effective as receiving it with sessions once per week among veterans with PTSD and substance use disorder in intensive outpatient substance use treatment. The main questions it aims to answer are:

  • Will the massed format help participants complete and benefit from Prolonged Exposure in terms of PTSD symptoms?
  • Will it help participants reduce substance use? Participants who are in intensive substance use treatment will be asked to complete Prolonged Exposure with either weekly sessions or multiple sessions per week.

Detailed Description

Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD, and delivering these treatments concurrent to SUD programming is recommended by the VA/DoD Clinical Practice Guidelines. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly). M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in military and Veteran populations. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M- PE delivery in of SUD intensive outpatient programming (IOP) in improving PTSD and other mental health outcomes and reducing dropout as compared to weekly PE delivery (W-PE) is the necessary next step in this critical research. The primary goal of this project is to determine if a promising way to treat PTSD among those with SUD, M-PE, will help Veterans with their PTSD symptoms and lead to better treatment completion rates more than PE delivered weekly and if the massed format will reduce substance use comparably to weekly PE among those in intensive SUD treatment. The study will also evaluate if M-PE helps Veterans function better and feel less depressed. M-PE is a one-on-one talk therapy that is delivered over twelve sessions several times a week. The therapy is brief because of the massed format so that it can be delivered at times when lengthy interventions may not be realistic, such as military mental health clinics on bases where military personnel may be getting ready to redeploy. The research team's preliminary work with Veterans in intensive SUD treatment showed M-PE to lead to improvements in PTSD and depression symptoms with no dropout, making this larger evaluation of M-PE compared to PE delivered in the traditional longer (weekly) format a critical next step. The study will accomplish this by randomly assigning participants who are in intensive SUD treatment to receive either M-PE or W-PE. The study will have 200 Veterans who served post 9/11 go through this study and the entire study is expected to take four years to complete. The study will run the study across four VAs (San Diego, Tampa, Chicago, and Atlanta).

Registry
clinicaltrials.gov
Start Date
September 1, 2024
End Date
August 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Veterans Medical Research Foundation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • who have served since September 2001
  • who are enrolled in a SUD IOP at a participating VA
  • meet DSM-5 criteria for a current SUD (Tobacco Use Disorder alone not sufficient for inclusion)
  • meet DSM-5 criteria for PTSD
  • report substance use at least 20 of the last 90 days
  • are able to give informed consent.

Exclusion Criteria

  • severe cognitive impairment
  • current suicidal or homicidal intent requiring immediate treatment
  • current unstable psychotic or manic symptoms not attributable to SUD

Outcomes

Primary Outcomes

Time Line Follow back (TLFB)

Time Frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use

Psychotherapy Completion Rates

Time Frame: 16 weeks

Percent of participants completing all sessions of psychotherapy, range is 0-100%, higher number means greater percent completed therapy

Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

Time Frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity

Secondary Outcomes

  • Brief Psychosocial Functioning Inventory (B-IPF)(At 4-, 16-, 28-, and 40-weeks post-first therapy session)
  • Patient Health Questionnaire-9 (PHQ-9)(At 4-, 16-, 28-, and 40-weeks post-first therapy session)
  • Client Satisfaction Questionnaire-8 (CSQ-8)(16 weeks)

Study Sites (4)

Loading locations...

Similar Trials